(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Influenza pipeline constitutes 120+ key companies continuously working towards developing 120+ Influenza treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Influenza Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Influenza Market.
The Influenza Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Influenza Pipeline Insight
Some of the key takeaways from the Influenza Pipeline Report:
- Influenza Companies across the globe are diligently working toward developing novel Influenza treatment therapies with a considerable amount of success over the years.
- Influenza companies working in the treatment market are Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and several others, are developing therapies for the Influenza treatment
- Emerging Influenza therapies such as mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, ALVR106 and others are expected to have a significant impact on the Influenza market in the coming years.
- On April 2024, ModernaTX, Inc announced results of a Phase 2, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults.
- On May 2024, Hoffmann-La Roche announced results of a Phase IIIb Multicenter, Single-Arm, Open-Label Surveillance Study of Susceptibility to Baloxavir Marboxil in Patients With Influenza.
- On October 2023, Bassett Healthcare announced results of a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).
Influenza Overview
Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. It typically spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Symptoms can range from mild to severe and include fever, cough, sore throat, muscle aches, fatigue, and headache. While most people recover within a few days to a couple of weeks, influenza can lead to serious complications, especially in vulnerable populations such as the elderly, young children, pregnant women, and those with underlying health conditions.
Each year, influenza viruses undergo genetic changes, leading to the emergence of new strains. This necessitates annual updates to the flu vaccine to provide protection against the most prevalent strains. Vaccination is the most effective way to prevent influenza and its complications. Additionally, practicing good hygiene, such as frequent hand washing and covering coughs and sneezes, can help reduce the spread of the virus.
Influenza poses a significant public health burden, causing seasonal outbreaks and occasional pandemics with widespread illness and mortality. Surveillance systems monitor influenza activity worldwide to inform public health responses, including vaccination campaigns and antiviral medication distribution. Despite these efforts, influenza remains a global health challenge, highlighting the importance of continued research and preparedness efforts to mitigate its impact.
Get a Free Sample PDF Report to know more about Influenza Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/influenza-pipeline-insight
Influenza Route of Administration
Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Influenza Molecule Type
Influenza Products have been categorized under various Molecule types, such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Influenza Pipeline Therapeutics Assessment
- Influenza Assessment by Product Type
- Influenza By Stage and Product Type
- Influenza Assessment by Route of Administration
- Influenza By Stage and Route of Administration
- Influenza Assessment by Molecule Type
- Influenza by Stage and Molecule Type
DelveInsight’s Influenza Pipeline Report covers around 120+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Influenza product details are provided in the report. Download the Influenza pipeline report to learn more about the emerging Influenza therapies – https://www.delveinsight.com/sample-request/influenza-pipeline-insight
Influenza Pipeline Analysis:
The Influenza pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Influenza with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
- Influenza key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Influenza Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Influenza market.
Download Sample PDF Report to know more about Influenza drugs and therapies – https://www.delveinsight.com/sample-request/influenza-pipeline-insight
Scope of Influenza Pipeline Drug Insight
- Coverage: Global
- Key Influenza Companies: Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and several others.
- Key Influenza Therapies: mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, ALVR106 and others.
- Influenza Therapeutic Assessment: Influenza current marketed and Influenza emerging therapies
- Influenza Market Dynamics: Influenza market drivers and Influenza market barriers
Request for Sample PDF Report for Influenza Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/influenza-pipeline-insight
Table of Contents
1. Influenza Report Introduction
2. Influenza Executive Summary
3. Influenza Overview
4. Influenza- Analytical Perspective In-depth Commercial Assessment
5. Influenza Pipeline Therapeutics
6. Influenza Late Stage Products (Phase II/III)
7. Influenza Mid Stage Products (Phase II)
8. Influenza Early Stage Products (Phase I)
9. Influenza Preclinical Stage Products
10. Influenza Therapeutics Assessment
11. Influenza Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Influenza Companies
14. Influenza Key Products
15. Influenza Unmet Needs
16 . Influenza Market Drivers and Barriers
17. Influenza Future Perspectives and Conclusion
18. Influenza Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services